# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
1 | 05-15-2024 | 03-31-2024 | 10-Q | |
2 | 03-29-2024 | 12-31-2023 | 10-K | |
3 | 12-11-2023 | 09-30-2023 | 10-Q |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Elevai Labs (NASDAQ:ELAB) reported quarterly losses of $(0.08) per share. This is a 27.03 percent increase over losses of $(0.1...
Preclinical results of EL-22 from a 2022 study demonstrated physiological (serum creatine kinase level), physical (body weight ...